^
Association details:
| Biomarker: | NOTCH2 mutation + NCOA4 mutation + PTEN mutation + EPHA3 mutation + KMT2D mutation |
|---|---|
| Cancer: | Marginal Zone Lymphoma |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Aggressive variant of splenic marginal zone lymphoma characterized using a cancer panel test and treated with rituximab-containing chemotherapy: A case report
Published date:
08/28/2020
Excerpt:
Although TP53 mutation was not detected, mutations in NOTCH2, NCOA4, PTEN, EPHA3, and KMT2D were identified....The patient was administered a rituximab-containing regimen and rituximab-maintenance therapy....The patient continues to exhibit a complete response.
DOI:
10.1097/MD.0000000000021938
